Design Therapeutics Inc (NASDAQ: DSGN) started the day on Thursday, with a price increase of 6.55% at $6.02, before settling in for the price of $5.65 at the close. Taking a more long-term approach, DSGN posted a 52-week range of $1.96-$6.91.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 0.00%. Meanwhile, its Annual Earning per share during the time was -138.68%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 23.25%. This publicly-traded company’s shares outstanding now amounts to $56.47 million, simultaneously with a float of $32.10 million. The organization now has a market capitalization sitting at $340.85 million. At the time of writing, stock’s 50-day Moving Average stood at $5.04, while the 200-day Moving Average is $3.86.
Design Therapeutics Inc (DSGN) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Design Therapeutics Inc’s current insider ownership accounts for 43.30%, in contrast to 41.71% institutional ownership. According to the most recent insider trade that took place on Aug 09 ’24, this organization’s Director sold 814,874 shares at the rate of 4.25, making the entire transaction reach 3,463,214 in total value, affecting insider ownership by 0.
Design Therapeutics Inc (DSGN) Earnings and Revenue Records
Design Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 23.25% and is forecasted to reach -1.17 in the upcoming year.
Design Therapeutics Inc (NASDAQ: DSGN) Trading Performance Indicators
Let’s observe the current performance indicators for Design Therapeutics Inc (DSGN). It’s Quick Ratio in the last reported quarter now stands at 41.42. The Stock has managed to achieve an average true range (ATR) of 0.37.
In the same vein, DSGN’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.90, a figure that is expected to reach -0.24 in the next quarter, and analysts are predicting that it will be -1.17 at the market close of one year from today.
Technical Analysis of Design Therapeutics Inc (DSGN)
If we take a close look at the recent performances of Design Therapeutics Inc (NASDAQ: DSGN), its last 5-days Average volume was 0.24 million that shows plunge from its year to date volume of 0.25 million. During the previous 9 days, stock’s Stochastic %D was recorded 96.57% While, its Average True Range was 0.36.
Raw Stochastic average of Design Therapeutics Inc (DSGN) in the period of the previous 100 days is set at 76.33%, which indicates a major fall in contrast to 100.00% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 83.79% that was higher than 82.02% volatility it exhibited in the past 100-days period.
